Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Caphosol Stories

2009-03-31 04:00:00

DOYLESTOWN, Pennsylvania and OXFORD, England, March 31 /PRNewswire/ -- EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, announced today the successful completion of its European launch of CAPHOSOL(R) for the prevention and treatment of oral mucositis associated with cancer therapy, as an adjunct to standard oral care. CAPHOSOL is also indicated for hyposalivation and xerostomia (dryness of the mouth or throat)...

2009-02-19 07:00:00

Transaction Value in Excess of $10 Million; Access Gains Second Source Manufacturing and Significant Clinical Trial Support DALLAS, and SEOUL, South Korea, Feb. 19 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) and JCOM Ltd, an affiliate of DONG-A Pharmaceuticals, the premier pharmaceutical company in the Republic of Korea, today announced the signing of a definitive licensing agreement under which JCOM and DONG-A will manufacture, develop and...

2008-10-17 18:00:23

A U.S. cancer specialist says there is little public awareness about a common cancer therapy side effect -- oral mucositis. Dr. James D'Olimpio of New York University School of Medicine and director of Supportive Oncology/Pain and Symptom Management at the Monter Cancer Center of North Shore University Hospital in Manhasset, N.Y., says an overwhelming majority -- 90 percent -- of more than 400 oral mucositis patients said this chemotherapy and radiation effect adversely affected their...

2008-10-16 06:00:10

PRINCETON, N.J., Oct. 16 /PRNewswire/ -- As millions of Americans participate in educational initiatives as part of National Breast Cancer Awareness Month, they should keep in mind an important yet under-recognized consequence of breast cancer therapy: oral mucositis, one of the most common and debilitating side effects of cancer treatment. Oral mucositis (OM) is a painful inflammation/ulceration of the mucous membranes in the mouth. It results from erosion of epithelial cells in the oral...

2008-09-03 00:00:24

Anadis Ltd. (ASX:ANX; OTC:ANDIY) an Australian biopharmaceutical company specializing in oral immunotherapy using naturally derived antibodies and other proteins is announcing the clinical protocol for its Cancer-related Mucositis Program was cleared by the Tel Aviv Souraski Medical Center's Institutional Review Board (IRB) and by the Israeli Ministry of Health (MOH). This enables the initiation of the clinical trial addressing this significant target at the medical center within a month....

2008-08-18 09:01:02

DALLAS, Aug. 18 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (BULLETIN BOARD: ACCP) and Milestone Biosciences, LLC ("Milestone") today announced the signing of a definitive license agreement under which Milestone will market Access' proprietary product MuGard(TM) in the United States and Canada. Milestone is a company recently started by former executives and sales representatives of companies with an established commercial presence in oncology, including MGI Pharma, Amgen and...

2008-06-30 09:02:20

At the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology's 2008 International Symposium on Supportive Care in Cancer (MASCC / ISOO) held last week in Houston, Texas, The GI Company reported secondary endpoints relating to Oral Mucositis Assessment Scale (OMAS) scores from the Company's Phase II clinical study, designed to evaluate the safety and efficacy of its lead clinical compound, Intestinal Trefoil Factor (rhITF) Oral Spray, in...

2008-06-24 09:03:23

Canopus BioPharma has announced that the South African Medicines Control Council has granted approval for a Phase II study in 30 cancer patients evaluating the protective effect of CB1400 on the gastrointestional tract from radiation-induced mucositis. This new trial is an important step forward in the development of CB1400 as a novel, preventative, anti-mucositis agent, the company said. Oral and gastrointestinal mucositis is a painful, debilitating, and sometimes fatal, side effect of...

2008-06-24 02:29:22

LOS ANGELES, June 23 /PRNewswire-FirstCall/ -- Canopus BioPharma, Inc. , is pleased to announce that the South African Medicines Control Council has granted approval for a Phase II study in 30 cancer patients evaluating the protective effect of CB1400 on the gastrointestional tract from radiation-induced mucositis. This new trial is an important step forward in the development of CB1400 as a novel, preventative, anti-mucositis agent. Oral and gastrointestinal (GI) mucositis is a painful,...